Skip to main content
Home > Week in Review > Offerings

Chronological Index of : Financial News

 Current Issue
  • Adynxx completes venture financing

    Adynxx raised $16 million in a series B round led by new investor TPG Biotech. Existing investor Domain Associates participated.Adynxx Inc., San Francisco, Calif.

    Published on 1/16/2017
  • Akers completes follow-on

    Akers raised $2 million through the sale of 1.7 million shares at $1.20 in a follow-on underwritten by Joseph Gunnar. Investors also received five-year warrants to purchase up to 833,500 shares at $1.50.Akers …

    Published on 1/16/2017
  • AOBiome completes venture financing

    AOBiome raised $30 million in venture financing from the iCarbonX ecosystem.AOBiome LLC, Cambridge, Mass.

    Published on 1/16/2017
  • CiVi Biopharma completes venture financing

    CiVi raised $40 million in a series A round from Tavistock Group.CiVi Biopharma Inc.

    Published on 1/16/2017
  • Eternygen completes venture financing

    Eternygen raised 8 million ($8.4 million) in a series A round led by Epidarex Capital. Evotec AG, VC Fonds Technologie and private investors also participated.Eternygen GmbH, Berlin, Germany

    Published on 1/16/2017
  • Integrated Diagnostics completes venture financing

    Integrated Diagnostics raised $6.1 million in a series C round from Baird Capital and InterWest Partners.Integrated Diagnostics Inc., Seattle, Wash.

    Published on 1/16/2017
  • Ivantis completes venture financing

    Ivantis raised $25 million in a series C round led by RA Capital Management. New investor Mrieux Dveloppement and existing investors participated.Ivantis Inc., Irvine, Calif.

    Published on 1/16/2017
  • Macrophage completes venture financing

    Macrophage raised 9 million ($11 million) in a series A round led by CRT Pioneer Fund. Novo Seeds and Aglaia Biomedical Ventures also participated.Macrophage Pharma Ltd., Windsor, U.K.

    Published on 1/16/2017
  • MatriSys Bioscience completes venture financing

    MatriSys raised $1.5 million in a convertible notes offering with Tech Coast Angels.MatriSys Bioscience, La Jolla, Calif.

    Published on 1/16/2017
  • Maverick Therapeutics completes venture financing

    Maverick Therapeutics raised $23 million in a series B round from existing investor MPM Capital and Takeda Pharmaceutical Co. Ltd.Maverick Therapeutics Inc., Brisbane, Calif.

    Published on 1/16/2017
  • Microbion completes venture financing

    Microbion raised $25 million in a venture financing from Quark Venture and GF securities.Microbion Corp., Bozeman, Mont.

    Published on 1/16/2017
  • Napo completes venture financing

    Napo raised $2 million in a secured convertible debt financing with Kingdon Capital Management.Napo Pharmaceuticals Inc., San Francisco, Calif.

    Published on 1/16/2017
  • OncoImmune completes venture financing

    OncoImmune raised $15 million in a series A round led by 3E Bioventures Capital.OncoImmune Inc., Rockville, Md.

    Published on 1/16/2017
  • POC Medical Systems completes venture financing

    POC Medical raised $21 million in a series A round led by BioVentures Investors. Sirius American Insurance, IFG Healthcare and MIA Investment also participated.POC Medical Systems Inc., Livermore, Calif.

    Published on 1/16/2017
  • Sera Prognostics completes venture financing

    Sera raised $40 million in a series C round led by Laboratory Corp. of America Holdings. Existing investors Domain Associates, InterWest Partners, Catalyst Health Ventures and the Bill & Melinda Gates Foundation …

    Published on 1/16/2017
  • SiteOne completes venture financing

    SiteOne raised $15 million in a series B round led by Amgen Inc. Existing investors Next Frontier Capital, 2M Companies, Mission Bay Capital, Sears Capital Management, BioBrit and Z Investments also participated.SiteOne…

    Published on 1/16/2017
  • T2 Biosystems completes debt financing

    T2 Biosystems drew down $40 million of a new $50 million debt facility from CRG. The final $10 million is available through July 27, 2018, subject to a regulatory milestone. The six-year loan bears interest at 12.5% …

    Published on 1/16/2017
  • Therachon completes venture financing

    Therachon raised $5 million in the final close of a series A round, bringing the total raised to $40 million. Versant Ventures, Inserm Transfer Initiative, OrbiMed and Bpifrance participated in the round.Therachon AG, …

    Published on 1/16/2017
  • Novavax financial update

    Novavax established an at-the-market program to sell up to $75 million of its shares. FBR is the sales agent.Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md.

    Published on 1/16/2017
  • Signet Healthcare financial update

    Signet Healthcare Partners closed its fourth fund at $137.2 million. The firm plans to invest the fund in 10-12 commercial companies, primarily in the pharmaceutical and medtech sectors.Signet Healthcare Partners, New …

    Published on 1/16/2017
  • Antibe completes private placement

    Antibe raised C$297,750 ($222,002) through the sale of 2 million units at C$0.15 in the second and final tranche of a private placement, bringing the total raised to C$2.7 million ($2.1 million). Each unit comprises a …

    Published on 1/9/2017
  • Appili completes venture financing

    Appili raised C$2.2 million ($1.6 million) in a venture round with existing investors, including Innovacorp, and new investors, including institutional investors.Appili Therapeutics Inc., Halifax, Nova Scotia

    Published on 1/9/2017
  • Ascentage completes venture financing

    Ascentage raised RMB500 million ($72 million) in a series B round led by Future Industry Investment Fund, a fund managed by SDIC. New investors Shiyu Capital, Hidragon Capital and Founder KIP Capital and existing …

    Published on 1/9/2017
  • Ascletis completes venture financing

    Ascletis raised $100 million in a series B round led by existing investor C-Bridge Capital. New investors QianHai Equity Investment, Focus Media Jiangnanchun Foundation and WTT Investment and existing investors Goldman …

    Published on 1/9/2017
  • Aurinia completes follow-on

    Aurinia raised $28.7 million through the sale of 12.8 million units at $2.25 in a bought deal underwritten by H.C. Wainwright and Cormark Securities. Each unit comprises a share and a five-year warrant to purchase 0.5 …

    Published on 1/9/2017

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993